EpiGenesis Pharmaceuticals, Inc. is a privately held biopharmaceutical company developing inhaled respiratory medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The Company's lead compound, EPI-12323 is an inhaled non-glucocorticoid steroid that targets the inflammatory and airway obstruction cascade in the asthmatic lung. EPI-12323 has pronounced anti-inflammatory and bronchodilator activity, and is not expected to exhibit any of the classical side effects of glucocorticoid steroids. In addition to EPI-12323, the Company has developed a novel platform technology based on the therapeutic use of Respiratory Antisense Oligonucleotides (RASON's) for addressing respiratory diseases.
View Top Employees from Epigenesis Pharmaceuticals| Website | http://www.epigene.com |
| Revenue | $6.2 million |
| Employees | 5 (0 on RocketReach) |
| Address | 2009 Eastpark Blvd, Cranbury, New Jersey 08512, US |
| Phone | (609) 409-6080 |
| Industry | Biotechnology, Manufacturing General, Manufacturing |
| Competitors | 4Sc Ag, Foldrx Pharmaceuticals, Light Chain Bioscience | Novimmune SA, Synairgen Research Ltd, Verona Pharma |
| SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Epigenesis Pharmaceuticals employee's phone or email?
Epigenesis Pharmaceuticals Questions
The Epigenesis Pharmaceuticals annual revenue was $6.2 million in 2024.
Epigenesis Pharmaceuticals is based in Cranbury, New Jersey.
The NAICS codes for Epigenesis Pharmaceuticals are [325, 3254, 32, 32541].
The SIC codes for Epigenesis Pharmaceuticals are [2834, 283, 28].
Related Companies
